What makes these stocks interesting?
Steinway Musical Instruments Inc. (LVB) Swings To Profit In Q3
- Q3 net income was $4.2 mln or $0.33/Shr versus loss $1.1 mln or $0.09/Shr last year.
- Q3 adj. net income was $4.4 mln or $0.36/Shr versus $1.8 mln or $0.14/Shr a year ago.
- Q3 net sales totaled $89.32 mln versus $89.76 mln last year.
***
Presidential Life Corp. (PLFE) Q3 Profit Rises
- Q3 net income was $5.2 mln or $0.18/Shr versus $2.9 mln or $0.10/Shr last year.
- Q3 total revenues rose 14% to $62.4 mln from $54.7 mln a year ago.
***
Ever-Glory International Group Inc. (EVK) Issues Q4, FY12 Guidance
- Projects Q4 total net sales in the range of $70 mln - $90 mln.
- Expects Q4 net income in the range of $3.6 mln - $5.0 mln.
- Sees FY12 total net sales in the range of $230 mln - $260 mln.
- Expects FY12 net income in the range of $9.5 mln - $12 mln.
***
SouFun Holdings (SFUN) Q3 Net Income Rises; Lifts FY12 Outlook
- Raises FY12 revenue guidance to between $400.0 mln and $420.0 mln from prior view $389.0 mln and $410.0 mln. Consensus - $411.53 mln.
***
Nektar Therapeutics (NKTR) Reports Top-Line Phase III Results From naloxegol Pivotal Study
Announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation or OIC. These Phase III KODIAC trials evaluated the safety and efficacy of naloxegol, an oral peripherally-acting, mu-opioid receptor antagonist for the treatment of OIC, a common side effect of prescription opioids.
Analysis of the data indicates that in KODIAC-04 both naloxegol doses demonstrated statistically significant results for the primary endpoint.
For comments and feedback: editorial@rttnews.com